For the rare NSCLC patient who achieves a CR on anti-PD-1 or PD-L1 therapy, do you consider either spacing out dosing intervals or offering treatment breaks?   

Taking a break is always worth discussing in situations like this. Often the patient and doctor are a bit reluctant (understandably), but in the absence of data from the pivotal trials to date it seems reasonable for some.